Clinical trials: Resistant Arterial Hypertension
Resistant Hypertension
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs.
- Trial name
- Bax24 (NCT06168409)
- Testing
- Baxdrostat
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- AstraZeneca
Resistant Hypertension, Hypercortisolism
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United…
- Trial name
- MOMENTUM (NCT06829537)
- Where
- 50 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Corcept Therapeutics
Resistant Hypertension
Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.
Hypertension is a serious public health issue, affecting approximately 30% of adults. Hypertension greatly contributes to the risk for heart disease and stroke, both among the top three leading causes of death in the Americas…
- Trial name
- NCT02926495
- Testing
- eCoin System
- Sponsor
- Valencia Technologies Corporation
Hypertension, Cardiovascular Diseases
LEPU Renal Denervation System for Resistant Hypertension
The purpose was to evaluate 6-month outcomes of renal denervation(RDN) for the treatment of resistant hypertension in Chinese patients in a prospective cohort study.
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- LEPU-RDN (NCT02536326)
- Testing
- LEPU Renal Denervation System
- Volunteers
- 50 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Patients, Resistant Hypertension
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
- Trial name
- NCT02515331
- Testing
- LHW090
- Where
- 16 sites in United States, Denmark and 4 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Metabolic Syndrome
Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome
A STUDY ON WHETHER AN ANTIHYPERTENSIVE MEDICATION PREVENTS DAMAGE TO WALLS OF VEINS IN FEMALE PATIENTS WITH THE METABOLIC SYNDROME (OVERWEIGHT AND OTHER DISORDERS).
- Trial name
- NCT00241150
- Testing
- VALSARTAN
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis
Difficult to Control Hypertension
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory…
- Trial name
- BOLD-HTN (NCT06343298)
- Testing
- MANP
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- E-Star BioTech, LLC
Resistant Hypertension, Difficult to Control Hypertension
Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
A randomized, double-blind, placebo-controlled multiple ascending dose study in hypertensive subjects on stable doses of at least three hypertensive drugs for at least 6 weeks prior to Screening.
- Trial name
- DTC/RHS (NCT05247528)
- Testing
- MANP
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- E-Star BioTech, LLC
Renal Artery Stenosis, Hypertension, Renovascular
Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
The purpose of this trial is to test how well the iCAST™ RX Stent works in patients diagnosed with atherosclerotic renal artery stenosis and whether or not increased blood flow by the stent will help to control blood pressure.
- Trial name
- ARTISAN (NCT01673373)
- Testing
- iCAST™ Rx Stent System
- Where
- 12 sites in United States
- Volunteers
- 68 people
- Sponsor
- Atrium Medical Corporation
Hypertension
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
- Trial name
- NCT00817635
- Testing
- LCI699, Eplerenone
- Where
- 38 sites in United States, Iceland
- Volunteers
- 155 people
- Sponsor
- Novartis
Hypertension
Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT
To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved…
- Trial name
- NCT00147563
- Testing
- Eplerenone
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Pfizer
Metabolic Syndrome, Hypertension
Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome
The purpose of this study is to study the effect of two doses of olmesartan medoxomil and amlodipine on vascular markers in hypertensive patients with metabolic syndrome.
- Trial name
- VAMOS (NCT00891267)
- Testing
- Olmesartan medoxomil tablets low dose, Olmesartan medoxomil tablets high dose, Amlodipine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Hypertension
Impact of Pacing Site and AV Delay on Blood Pressure in Hypertensive Patients
The purpose of this study is to test whether the A-V sequential pacing strategy shown to effectively reduce blood pressure in a dog model of hypertension also reduces blood pressure acutely in patients with hypertension (systolic…
- Trial name
- NCT02382484
- Testing
- A dual chamber pacing system (BackBeat Medical)
- Where
- China
- Volunteers
- 19 people
- Sponsor
- BackBeat Medical Inc
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Uncontrolled Hypertension
Feasibility Study of Renal Denervation for the Treatment of Resistant Hypertension
The aim of this study is to assess the potential therapeutic benefit of catheter-based renal sympathetic denervation using therapeutic unfocussed ultrasound in a single-arm feasibility trial.
- Trial name
- SoundITV (NCT01865591)
- Testing
- Ultrasound-based Renal Denervation
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Sound Interventions, Inc.
Hypertension
Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
This is a prospective, multicenter, feasibility study on the safety and efficacy of renal denervation in patients with resistant hypertension.
- Trial name
- EnligHTN-I (NCT01438229)
- Testing
- St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
- Where
- 4 sites in Australia, Greece
- Volunteers
- 47 people
- Sponsor
- Abbott Medical Devices
Diabetes Mellitus Type 2, Hypertension
MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)
The purpose of this study is to determine whether MC-1 alone and in combination with an ACE inhibitor is effective in reducing blood pressure and metabolic dysfunctions associated with diabetes
- Conditions
- Diabetes Mellitus Type 2, Hypertension, Metabolic Syndrome
- Trial name
- NCT00157729
- Testing
- pyridoxal-5'-phosphate with and without ACE inhibitor
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Medicure
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Hypertension, Type 2 Diabetes
Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive
The objective of the study is to evaluate the safety of multi-organ denervation using the Integrated Radio Frequency (iRF) Denervation System. and to understand any potential improvement in hypertension and glycemic control.
- Conditions
- Hypertension, Type 2 Diabetes, Metabolic Syndrome
- Trial name
- MODUS (NCT04917393)
- Testing
- iRF System Multi-organ Denervation, Control Procedure
- Where
- 2 sites in Georgia
- Volunteers
- 45 people
- Sponsor
- Metavention
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.